Real-World Assessment of Switching from a Dipeptidyl Peptidase-4 Inhibitor to Exenatide Once-Weekly in Patients with Type 2 Diabetes

被引：0
|
作者：
Gorgojo-Martinez, Juan J.
Gargallo-Fernandez, Manuel A.
Brito-Sanfiel, Miguel A.
Lisbona-Catalan, Arturo
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1118-P
引用
收藏
页码：A297 / A297
页数：1
相关论文
共 50 条
  • [1] Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes
    Kawasaki, Eiji
    Nakano, Yuko
    Fukuyama, Takahiro
    Uchida, Aira
    Sagara, Yoko
    Tamai, Hidekazu
    Tojikubo, Masayuki
    Hiromatsu, Yuji
    Koga, Nobuhiko
    WORLD JOURNAL OF DIABETES, 2021, 12 (12) : 2087 - 2095
  • [2] Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes
    Ito, Hiroyuki
    Ando, Shigenori
    Tsugami, Emiko
    Araki, Rie
    Kusano, Eiji
    Matsumoto, Suzuko
    Uemura, Kosuke
    Nishio, Shinya
    Antoku, Shinichi
    Yamasaki, Tomoko
    Mori, Toshiko
    Togane, Michiko
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 153 : 41 - 48
  • [3] Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis
    Stoimenis, Dimitrios
    Karagiannis, Thomas
    Katsoula, Anastasia
    Athanasiadou, Eleni
    Kazakos, Kyriakos
    Bekiari, Eleni
    Matthews, David R.
    Tsapas, Apostolos
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (09) : 843 - 851
  • [4] Predictors of Glycemic and Weight Response to Exenatide Once-Weekly in Patients with Type 2 Diabetes in a Real-World Setting
    Gorgojo-Martinez, Juan J.
    Brito-Sanfiel, Miguel A.
    Gargallo-Fernandez, Manuel A.
    Lisbona-Catalan, Arturo
    DIABETES, 2017, 66 : A297 - A297
  • [5] Once-weekly exenatide in type 2 diabetes
    Dinesh M. Parmar
    Shilpa P. Jadav
    International Journal of Diabetes in Developing Countries, 2011, 31 : 121 - 122
  • [6] Once-weekly exenatide in type 2 diabetes
    Parmar, Dinesh M.
    Jadav, Shilpa P.
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2011, 31 (02) : 121 - 122
  • [7] Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
    Kamrul-Hasan, A. B. M.
    Alam, Muhammad Shah
    Talukder, Samir Kumar
    Dutta, Deep
    Selim, Shahjada
    ENDOCRINOLOGY AND METABOLISM, 2024, 39 (01) : 109 - 126
  • [8] Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
    Hanefeld, Markolf
    Herman, Gary A.
    Wu, Mei
    Mickel, Carolyn
    Sanchez, Matilde
    Stein, Peter P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) : 1329 - 1339
  • [9] A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
    Shankar, R. Ravi
    Inzucchi, Silvio E.
    Scarabello, Victoria
    Gantz, Ira
    Kaufman, Keith D.
    Lai, Eseng
    Ceesay, Paulette
    Suryawanshi, Shailaja
    Engel, Samuel S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (10) : 1853 - 1860
  • [10] A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes
    Gantz, Ira
    Okamoto, Taro
    Ito, Yuka
    Okuyama, Kotoba
    O'Neill, Edward A.
    Kaufman, KeithD.
    Engel, Samuel S.
    Lai, Eseng
    DIABETES OBESITY & METABOLISM, 2017, 19 (11): : 1602 - 1609
12345